Acutaas Chemicals Ltd Q3 FY2026 Concall Summary

Key Takeaways

• 43% revenue growth, guidance raised: Revenue surged 43% YoY, prompting management to upgrade FY26 growth guidance from 25% to ~30% and EBITDA margin guidance to 32-35%.
• CDMO is the breakout story: Five commercialized products and four more validated this year underpin the ₹1,000 crore FY28 target; the business is growing exponentially and driving the mix shift that expanded gross margin by 1,073 bps.
• Battery chemicals enters commercialization: The new Jhagadia block is inaugurated, VC and FEC orders are in hand, and commercial supply begins by end of Q4 FY26, with two more products joining from mid-FY27.
• Portfolio cleanup masks base-business strength: Ex-CDMO growth moderated because management deliberately shed low-margin products; the remaining book shows "quality growth" and the BFC business has turned the corner from its bottom.
• What to watch next quarter: Whether VC/FEC commercial shipments actually start by quarter-end, the pace of Ankleshwar utilization ramp from 40%, and any CDMO contract announcements that would give visibility to the FY28 target.

CDMO: The Growth Engine

• Exponential trajectory: Five products already commercialized, four more validated in FY26 and expected to contribute from FY27, with additional sampling and validation batches in the pipeline for coming quarters.
• ₹1,000 crore FY28 target: The guidance is based on customer expectations and the current pipeline of validated and soon-to-be-validated products, though management declined to specify how many molecules will get there, citing the difficulty of predicting commercialization timelines.
• Confidentiality limits disclosure: Management will not break out CDMO revenue contribution, product mix between pharma and agro, or contract details, all constrained by the confidentiality nature of CDMO agreements.
• Product concentration risk is being addressed: The four validated products plus many more in the pipeline, alongside electrolyte and semiconductor chemicals emerging as growth engines, are the deliberate derisking strategy.

Naresh Patel: "Overall, I believe that FY 2028, these three business verticals will operate as independent self-sustaining growth engines, each contributing meaningfully to our overall top line."

Battery Chemicals: From Capex to Commercialization

• Jhagadia block live: The dedicated battery chemicals block was inaugurated on January 19, 2026, and Q4 FY26 is primarily trial production, testing, validation and commencement of commercial operations.
• VC and FEC orders in hand: Commercial supply is expected to start by the end of Q4 FY26, with significant ramp-up from Q1 FY27. Contracts are fixed-price with variability clauses for key raw materials and currency.
• Two more products added: Beyond VC and FEC, two additional battery chemicals products are expected to contribute from mid-FY27, though management declined to disclose capacity numbers for this expansion.
• Phase 2 capex on track: Implementation is underway with completion expected by Q1 FY27, roughly within the next six months from the January call.[8-9]
• Margin profile: Electrolyte additives will sit below traditional pharma intermediates margins and above the existing paraben commodity chemical business; margins will start lower due to operability and scale but improve as the business scales up faster to capture operating efficiencies.
• Long-term supply philosophy: Management emphasized it is driven by long-term supply contracts rather than short-term market-movement gains, a stance that shapes the fixed-plus-variable contract structure already signed.

Abhishek Patel: "We believe not on the short-term gaining of this market movement, we more driven by the long-term supply contract."

Margins: The Mix Shift at Work

• Gross margin jumped 1,073 bps YoY to 57%: The expansion was driven by improved product mix as higher-margin CDMO revenue grew exponentially and low-margin products were deliberately exited from the ex-CDMO portfolio.
• EBITDA margin reached 38.3%, up 1,335 bps YoY: The lift came from gross margin expansion plus operating leverage, with other expenses declining on energy savings from the solar plant, fewer consumable and repair items, and improved internal processes.
• Margin improvement is multi-lever: Management credited not just R&D but process improvement, energy, technology, operational efficiency and utility, all working in combination.
• FY26 guidance upgraded: EBITDA margin guidance raised from 28-30% to 32-35%, but management declined to guide on FY27 margins, saying that discussion will happen at the relevant time.
• Electrolyte additive margins will dilute initially: The new business will start below pharma intermediates margins and improve with scale, a headwind to watch as battery chemicals ramp.

Abhishek Patel: "This is because we have carefully taken strategic decision to review our product portfolio and let go low-margin products. That's why you see now quality growth is coming."

Ex-CDMO Portfolio: Quality Over Volume

• Growth moderated by design: The non-CDMO pharma intermediates business grew in high single digits, a deliberate slowdown after management reviewed the product portfolio and shed low-margin products to prioritize quality growth over volume.
• BFC business turns the corner: Baba Fine Chem revenue hit a bottom last quarter and has started a positive trajectory this quarter, though management expects the recovery to be a slow process and declined to give FY26 guidance for the subsidiary.
• Generic products are the non-CDMO driver: A couple of generic products performed well this financial year and last quarter, with new products expected to join in the coming quarter.
• Ankleshwar utilization at 40%: The plant was completed only last quarter, so products still need validation from the newer site; both newer products and some existing products are being shifted or transferred there.
• Specialty chemicals grew 16.5% YoY: Consistent growth in the commodity chemical sub-segment with high volume and stable pricing, supported by the BFC recovery.

Abhishek Patel: "I think the last quarter was more of a kind of bottom point for us from where we have started positively from this quarter onwards."

Competitive Position & R&D Moat

• Multi-chemistry capability is the USP against China: The company does multiple chemistry for any product at large scale, and for the majority of its top products it is the leader with over 70-80% market share.
• 680 molecules developed in R&D: The depth of the chemistry library is a foundational asset that helps the company understand and execute complex synthesis, underpinning both the CDMO pitch and the ability to defend market share.
• R&D headcount expected to increase: Management expects the R&D team to bump up over the next 12 months, signaling continued investment in the pipeline.
• Direct US export exposure is minimal: Only a very small amount of direct export goes to the US market, largely from the Baba Fine Chem subsidiary, limiting tariff risk.
• EU FTA seen as a welcome tailwind: Management believes the company may be a beneficiary if a free trade agreement materializes, though no specifics were offered.

Naresh Patel: "We have more than 680 molecules developed in our R&D. So that will help us to understand the chemistry."

Capex Pipeline: Building the Three Engines

• Pilot plant capex delayed: Completion now expected by Q1 FY27, a slight push from the original timeline.
• Indichem JV on track: The semiconductor chemicals joint venture capex is progressing as planned, with completion expected by the end of calendar year 2026 and revenue to follow from the next calendar year.
• Indichem economics: Asset turn is expected in the range of 1 to 1, with higher EBITDA margins than the pharma business.
• Ankleshwar future capex is premature: Current capacity covers growth requirements until FY28; management may come up with a new capex plan in roughly 1.5 years based on market conditions.
• Three-year growth visibility: Management stated the company would grow more than 25% at the revenue level for the next three years, with all three verticals standing on their own feet and contributing meaningful profit by FY28.

Abhishek Patel: "We do multiple chemistry for any of the product at a large scale, which is a key or USP for us as against any Chinese competition."

Guidance & Commitments

Key Metrics